Perturbations in iron homeostasis and iron accumulation feature in several neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD) and Amyotrophic lateral sclerosis (ALS). Proteins such as α-synuclein, tau and amyloid precursor protein that are pathologically associated with neurodegeneration are involved in molecular crosstalk with iron homeostatic proteins. Quantitative susceptibility mapping, an MRI based non-invasive technique, offers proximal evaluations of iron load in regions of the brain and powerfully predicts cognitive decline. Further, small molecules that target elevated iron have shown promise against PD and AD in preclinical studies and clinical trials. Despite these strong links between altered iron homeostasis and neurodegeneration the molecular biology to describe the association between enhanced iron levels and neuron death, synaptic impairment and cognitive decline is ill defined. In this review we discuss the current understanding of brain iron homeostasis and how it may be perturbed under pathological conditions. Further, we explore the ramifications of a novel cell death pathway called ferroptosis that has provided a fresh impetus to the "metal hypothesis" of neurodegeneration. While lipid peroxidation plays a central role in the execution of this cell death modality the removal of iron through chelation or genetic modifications appears to extinguish the ferroptotic pathway. Conversely, tissues that harbour elevated iron may be predisposed to ferroptotic damage. These emerging findings are of relevance to neurodegeneration where ferroptotic signalling may offer new targets to mitigate cell death and dysfunction.
Introduction
Iron is the most abundant transition metal on Earth and essential for life. Iron availability in primordial oceans allowed for its incorporation in living organisms. Metabolic processes catalysed by iron or by ironsulfur clusters may be among the first of such processes to evolve on Earth and essential for the emergence of carbon-based life [22, 214] . The photolysis of water by photosynthesis around 2.45 billion years ago introduced a new global poison i.e. oxygen, causing what is described as the Great Oxygenation Event [191] . The resultant oxidising environment transformed iron into a limiting factor for life processes due to the limited solubility of the oxidised iron cation.
The ability of iron to cycle through its oxidation states and form coordination bonds is utilised by many enzymes to carry out their catalytic function. Iron has thus emerged as an indispensable co-factor for proteins involved in essential (respiration, DNA replication, cell division) and specialised (oxygen transport, neurotransmission) cellular functions. Iron can serve as a potent oxidant that can wreak havoc on biomolecules, ironically endangering the life that it helps facilitate. This conundrum necessitated the evolution of homeostatic mechanisms to ensure the availability of this critical element while mitigating potential oxidative damage. In the body iron levels are maintained through the precise uptake of iron from the diet. However, the body has no specific physiological mechanism for iron excretion. Iron thus tends to accumulate in certain tissues with age. The brain is a major organ where iron accumulates with age, especially in regions of pathological relevance. The study of monogenic genetic disorders that affect iron homeostasis, and indications from dietary studies, have established that brain iron homeostasis is mostly independent of systemic iron homeostasis [15] . Furthermore, indicators of systemic iron levels weakly correlate with iron in the brain. Several neurodegenerative conditions including Alzheimer's disease (AD) andseverity [15] . However, the iron-mediated events that may promote neurodegeneration appear to be more intricate than iron-associated oxidative damage. Here we review the development of the "iron-hypothesis" of neurodegeneration, shifting our focus beyond iron toxicity to consider the recently (re)discovered iron-dependent programmed cell death pathway called ferroptosis.
Iron homeostasis in the brain

Overview
Iron is essential for brain health and development. Iron-dependent enzymes and proteins are required for development of synapses, myelination, and production and turnover of neurotransmitters [28] . Further, the brain is energetically reliant on iron-dependent proteins involved in cellular respiration. Iron deficiency during early development is deleterious to normal brain development and negatively impacts brain function including IQ, cognition, motor skills, and social behaviour [14] . Dietary iron deficiency during early development leads to severe iron deficit in the brain as iron stores are primarily utilised to maintain haemoglobin levels in the blood. While impaired brain development during childhood, resulting from iron deprivation, can be reversed through an iron-replete diet, changes that have occurred during early infancy tend to persist despite a correction in iron status [14] .
Iron levels in the paediatric brain are lower than that in the adult brain. Iron accumulates in the adult brain largely as a function of age and is reportedly influenced by the body mass index (BMI) and smoking [166] . Iron accumulation in the brain is spatially and temporally heterogeneous. Higher concentrations of iron within the brain are preferentially found in the nucleus accumbens, substantia nigra (SN), deep cerebellar nuclei and parts of the hippocampus [197, 61, 85, 90] . However, the rate of brain iron accumulation varies with the stage of brain development. Interestingly, brain iron accumulation is a characteristic feature in several neurodegenerative disorders such as AD, PD, motor neuron disease (MND)/amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and a group of disorders categorised as Neurodegeneration with Brain Iron Accumulation (NBIA). Furthermore, brain iron accumulation occurs in regions implicated in disease pathology and may accompany oxidative stress, inflammation, and cell death.
Iron import in the brain
The blood-brain barrier (BBB) mounts a formidable defence for the brain against foreign molecules and separates the iron homeostasis of the brain from that of the periphery. This compartmentalisation can be clearly observed in conditions of iron excess, such as haemochromatosis, where iron-associated cellular damage occurs in several peripheral organs but not the brain [43, 151, 181] . Brain capillary endothelial cells (BCECs) maintain the integrity of the BBB (Fig. 1) . Their function is in turn facilitated, at their abluminal surface, by astrocytes that serve to detoxify/neutralise inbound solutes that may perturb the extracellular balance of the brain [149] . This protective mechanism allows for a highly regulated uptake of iron in the brain [43, 206] . Iron import into the brain starts by binding of blood-circulating transferrin (Tf) to transferrin receptor 1 (TfR1) on the surface of BCECs and internalisation of the Tf/TfR1 complex [206] . However, the mechanism of iron transport across the BCECs is unresolved and two likely scenarios have emerged (Fig. 1) . In the classical model iron is released from Tf inside endosomal compartment of BCECs under a low pH (around 5.5) achieved by the activity of proton pumps. This is followed by reduction of iron to its ferrous state in the presence of ferrireductases, such as STEAP3 [23] . Subsequent transport of iron across the endosomal membrane into the cytosol is mediated by the divalent metal transporter 1 (DMT1). Ferrous iron may then be used, stored into ferritin or effluxed across the cell membrane by the iron exporter ferroportin 1 (FPN). Iron export through FPN is accompanied by oxidation of iron, which can be accomplished by ferroxidases such as ceruloplasmin (Cp) and hephaestin and binding to extracellular transferrin [23] . An alternate model (transcytosis model) arose due to confounding evidence regarding the expression of DMT1 and FPN in BCECs [23, 149, 150] . According to this model the iron-loaded Tf (holo-Tf) is transported across the cytosol of BCECs to the abluminal site and is then directly released in the brain [174] . This model is supported by the observation that cultured bovine BCECs cycle Tf-TfR1 complexes and that holo-Tf transported across these cells may not undergo intraendothelial degradation [47, 174] . However no evidence has emerged to demonstrate the transport of Tf from the systemic circulation across BCECs into the brain [43, 150, 202] .
Iron homeostasis in glial cells
Astrocytes are essential support cells in the neurovascular unit and serve to release the iron supplied by BCECs to the neurons while mitigating iron toxicity [1, 23] . To this end astrocytes are specialised for iron export. The export of iron from astrocytes is reliant on Cp [109, 114] , which they express both as a secreted protein and in a membrane-bound glycosylphosphatidylinositol (GPI)-anchored form [160, 161] . Astrocytes, at least in vivo, appear to be devoid of TfR1 and steps involved in the import of iron in these cells are unclear [15, 223] . DMT1 may facilitate iron import in astrocytes [99, 100, 117, 148, 162] .
Oligodendrocytes are macroglial cells responsible for the synthesis of myelin and are the principal cells in the brain that stain for iron [15, 16, 209] . Iron is essential for myelin formation and iron deficiency leads to hypomyelination and associated disorders [208] . Oligodendrocytes may acquire iron in a TfR1-independent manner [149, 209] . Ferritin, the high capacity iron storage protein in the cytosol of most mammalian cells, has been suggested as a possible source of iron for oligodendrocytes [37, 170, 183, 209, 237] . Indeed, Tim2 (T-cell immunoglobulin mucin domain 2 protein) has been identified as a specific receptor mediating ferritin uptake and internalisation by oligodendrocytes in rodents [106, 209] . Furthermore, an analogous protein Tim1 has been recently identified as a receptor for ferritin in human oligodendrocytes [34] . This suggests that direct receptor-mediated endocytosis of ferritin may be the predominant mode of iron uptake in oligodendrocytes. Iron and ferritin content in oligodendrocytes increases with age [16] . Oligodendrocytes express Tf and FPN possibly for intracellular transport and efflux of iron, respectively [149] .
Microglia originate as circulating monocytes that migrate to the brain during the developmental stage and then differentiate into quiescent microglial cells [143] . The migrating monocytes are laden with iron and consequently possess abundant ferritin, both of which are gradually lost during the transformation to microglial state [31, 147] . In rodents, cultured microglial cells have been shown to release ferritin that increases survival of oligodendrocytes [237] . Further, lipopolysaccharide-induced oligodendrocyte genesis in the rat spinal cord occurs following a robust infiltration of ferritin-positive microglia [185, 186] . Microglia may thus serve as a source of iron-laden ferritin for oligodendrocytes [209] .
Iron homeostasis in neurons
Iron uptake in neurons occurs via TfR1 which binds and internalises holo-Tf (Fig. 2) . Following endosomal acidification, dissociation of iron from Tf and subsequent reduction, DMT1 facilitates the transfer of iron across the endosomal membrane into the cytosol. This available iron can then be used for neuronal function and metabolism. Excess iron may be stored or exported across the plasma membrane. Ferritin can be expressed in neurons to store and detoxify excess iron [92] . FPN exports ferrous iron from neurons which is then bound by Tf, following oxidation by circulating or astrocyte-tethered Cp in the interstitium. The amyloid precursor protein (APP) stabilises FPN at the neuronal cell surface facilitating iron efflux. The trafficking of APP to the cell membrane is supported by the microtubule-associated protein tau (Fig. 2) [122] .
Iron homeostasis is regulated in all mammalian cells by the activities of cytosolic iron response proteins (IRP1/2) and is modulated by intracellular iron levels. In neurons IRP2 serves as the main sensor of labile (available intracellular) iron [142] . Under condition of low intracellular iron IRPs bind to the iron-regulatory elements (IREs) located on the stem-loop structures of the untranslated region (UTR) of mRNA of iron-responsive proteins (Fig. 3) . The mRNAs that harbour IREs in their 3'-UTR (e.g. TfR1 and DMT1) are stabilised by IRP binding leading to enhanced translation while on the contrary, the translation of mRNA that harbour IREs in their 5'-UTR (e.g. ferritin, FPN, APP, α-synuclein) is repressed [3] . In this way, IRP/IRE system upregulates TfR1 and DMT1 in iron limiting conditions while in condition of iron excess, the lack of IRP binding to IREs allows for an increase in iron storage (ferritin) and export (FPN). Elevated iron directly impacts on the translation of APP and α-synuclein that are implicated in several neurodegenerative conditions including AD and PD [177, 178] . Fig. 1 . Iron import in the brain. Brain capillary endothelial cells (BCECs) maintain the integrity of the bloodbrain-barrier while allowing for the uptake of iron bound to transferrin (Tf) from the blood. Astrocytes at the abluminal surface of BCECs facilitate this highly regulated uptake of iron in the brain. Blood-circulating transferrin carrying iron bound by transferrin receptor 1 (TfR1) on the surface of BCECs and followed by internalisation of the Tf/TfR1 complex. Two alternative models have been suggested for the import of iron across BCECs. According to transcytosis model (i) the iron-loaded Tf is transported across the BCEC cytosol to the abluminal site and is directly released in the brain. According to the (ii) classical model iron is released from Tf in endosomes following the acidification of this compartment. The released iron is then reduced via ferrireductases and subsequently transported across the endosomal membrane into the cytosol by the divalent metal transporter 1 (DMT1). The released iron may then be used, stored (in ferritin) or effluxed [via ferroportin 1 (FPN)]. Iron export is facilitated through ferroxidases such as ceruloplasmin (Cp) and hephaestin (not shown) that oxidise iron prior to its loading onto Tf. Fig. 2 . Crosstalk between ferroptosis and iron homeostasis. Lipid peroxides (L-OOH) that ignite ferroptotic death are produced through auto-oxidation and/or enzymatic activity of lipoxygenases on lipid esters generated from lipids via the activity of ACSL4 and LPCAT3. Pharmacological inhibitors of lipoxygenases (e.g. zileuton) and genetic ablation of ACSL4 can limit the process of generation of L-OOH thus limiting ferroptosis. Glutathione peroxidase 4 (GPX4) plays a central role in the ferroptotic pathway though its ability to convert L-OOH to lipid alcohols (L-OH). Pharmacological inhibition of GPX4 can execute ferroptosis in a variety of cell types. This is achieved through direct inactivation of GPX4 (e.g. RSL3), or by limiting cellular stores of its cofactor, glutathione (GSH). GSH levels in cells can be limited though pharmacological inhibition of γGCL (e.g. by BSO) or through blocking of xCT (e.g. by erastin) thus limiting uptake of cysteine, a required substrate for GSH synthesis. Iron exacerbates ferroptosis potentially by catalysing/facilitating lipid peroxidation. Iron chelators (e.g. deferiprone, deferoxamine) are potent inhibitors of ferroptosis. Iron uptake in neurons is facilitated through circulating transferrin bound iron (Tf-Iron) which is endocytosed by binding to transferrin receptor 1 (TfR1). Endosomal iron is released to the cytosol through the activity of divalent metal transporter 1 (not shown) following which iron is either utilised (e.g. synthesis of haem and iron-sulfur clusters in mitochondria), stored in ferritin, or exported through the activity of ferroportin (FPN). The amyloid precursor protein (APP) facilitates the iron export function of FPN by maintaining it at the cell membrane. This "tethering" of APP and FPN is facilitated by normal cytosolic levels of tau. Autophagic degradation of ferritin (ferritinophagy) and catabolism of haem that may enhance labile iron can enhance ferroptosis sensitivity in cells. Conversely, silencing of TfR1 and depletion of Tf may enhance resistance to ferroptotic death.
Role of iron in neurodegeneration
Iron is essential for normal brain development and cognitive function. The deficiency of iron thus adversely impacts on neurological development and function, especially in prenatal or early postnatal stages, where the dysfunction may affect memory and learning ability [171] . Iron progressively accumulates in the brain with age with a greater accumulation observed in the cortex and the nuclei of the basal ganglia viz. SN, putamen, globus pallidus and caudate nucleus; iron accumulation in these regions is associated with neurodegenerative disorders [15] .
Neurodegenerative disorders that are associated with high brainiron include AD, PD, HD, MND/ALS, infantile neuroaxonal dystrophy (INAD), Schindler disease, and other neuroaxonal dystrophies termed NBIA disorders [15, 74, 96, 154, 216] . Further, iron overload is associated with a subset of psychiatric diseases [44, 71, 97] . While the deleterious effects of enhanced iron in the brain have been ascribed to an oxidative damage component, the recently (re)discovered iron-mediated regulated cell death pathway, ferroptosis, is now under scrutiny for its role in neurodegeneration and cognitive impairment.
Iron in AD pathology
AD is the leading cause of dementia and is a progressive neurodegenerative disorder affecting cortical and hippocampal neurons. AD is characterised by the accumulation of extracellular senile plaques composed primarily of aggregated amyloid beta peptide (Aβ), and intracellular neurofibrillary tangles (NFTs) formed by hyper-phosphorylated microtubule-associated protein tau. While the pathology of AD is largely ascribed to a toxic accumulation of Aβ, clinical strategies that have reduced Aβ burden have not been successful in limiting disease progression [155] . Several other factors such as altered metal homeostasis, inflammation, oxidative stress, defects in autophagy and lysosomal function, mitochondrial dysfunction, and impaired glial function have been implicated in AD [15, 24, 156] . While some of these factors are amenable to therapeutic targeting these avenues have been largely neglected [15, 24] . The strongest genetic risk factor for AD, apolipoprotein E (ApoE) 4 allele exerts a gene dosage effect on the age of onset of AD however the underlying mechanism of pathogenesis remains unclear [104] .
Iron accumulates in the AD brain and is associated with senile plaques and NFTs [39, 84, 129, 198, 199] . Using magnetic resonance imaging (MRI) iron accumulation is preferentially observed in the AD affected regions of the brain viz. parietal cortex, motor cortex, and hippocampus [12, 13, 18, 54, 82, 119, 131, 165, 204] . Systemic changes in iron homeostasis accompany AD such as decreased iron in plasma, resulting from Tf desaturation, and decreased cellular iron export indicated by decreased expression of aconitase 1, Cp and APP in peripheral blood mononuclear cells of AD patients vs. normal subjects [69, 87, 93, 94] . Several studies implicate iron in the aggregation, oligomerisation, amyloidosis, and toxicity of Aβ peptides [101, 127, 135, 187] . Some studies suggest that Aβ lacks toxicity and the oxidative damage associated with its aggregation is due to the redox active metals it binds, viz. iron and copper, leading to production of potent oxidants such as hydrogen peroxide [102, 111] . Further, iron can induce hyper-phosphorylation and aggregation of tau [30, 130, 231] . Tau accumulation in NFTs is associated with an induction of haem oxygenase-1 which may further exacerbate oxidative stress through the release of ferrous iron by the catabolism of haem [163, 184, 219, 221] . These events can be mitigated through iron chelation [2, 201] .
Iron status may directly impact the translation of APP through an Iron-responsive mRNA element (IRE) in its 5'-UTR [177, 178] . APP is a transmembrane protein that through amyloidogenic processing results in Aβ [105, 26] . Neuronal APP is normally processed thorough a nonamyloidogenic pathway involving cleavage by α-secretase followed by cleavage by γ-secretase. Amyloidogenesis occurs when APP is first cleaved by β-secretase and then γ-secretase. Iron modulates the α-secretase mediated cleavage of APP [20] . Further, the activation of α-secretase and β-secretase is modulated proteolytically by furin; the levels of furin protein are reduced in condition of excess iron, which favours β-secretase activity, thus promoting amyloidogenesis [195, 221] . APP can also facilitate the efflux of iron from neurons by stabilizing FPN on the cell membrane and APP depletion leads to iron accumulation in cultured neurons and in mouse models [63, 141, 218, 224] . Further, tau deficiency leads to iron accumulation, which is associated with impaired APP trafficking to the cell membrane [122] .
The association of iron with AD pathology is supported by the finding that CSF ferritin levels positively correlate with cognitive decline and can predict the transition from mild cognitive impairment to AD in a longitudinal study [6] . Ferritin levels also correlated with ApoE protein levels suggesting a possible bearing of iron homeostasis on the mechanism by which ApoE isoforms may influence AD pathogenesis Fig. 3 . Translational modulation of iron homeostatic proteins by intracellular iron levels. Under iron depleted condition IRPs bind to the iron-regulatory elements (IREs) located on the stem-loop structures of the untranslated region (UTR) of mRNA of iron-responsive proteins. IREs on the 3'-UTR of mRNAs (e.g. TfR1 and DMT1) allow for stabilisation of these mRNA by IRP binding leading to enhanced translation of proteins. Alternatively, IREs in their 5'-UTR of mRNAs (e.g. ferritin, FPN, APP, α-synuclein) cause repression of translation following IRP binding leading to repression of corresponding protein levels. IRP/IRE system upregulates TfR1 and DMT1 in iron limiting conditions while in condition of iron excess, the lack of IRP binding to IREs allows for an increase in iron storage (ferritin) and export (FPN). [6] . CSF ferritin level is strongly associated with cognitive decline in carriers of ApoE4 allele [5] Further, iron treatment in cultured neurons and astrocytes upregulates the transcription of ApoE [229] . Higher magnetic susceptibility, a proxy for tissue iron, in the hippocampus predicted an accelerated decline in cognition in amyloid positive subjects in over 6 years in another longitudinal study [7] . Lower cortical iron may confer a reduced vulnerability to cognitive loss with age in the presence of age-related neuropathologies [212] . In post mortem brains, from AD patients and healthy controls, grey matter positive for amyloid plaques showed higher magnetic susceptibility (consistent with greater iron burden) compared to grey matter free of amyloid plaque [207] . Longitudinal studies have described that iron burden is associated with a marked increase in the rate of cognitive decline in individuals who scan positive for brain amyloid [7, 62, 212, 213] .
Iron in PD pathology
PD is a neurodegenerative disease that is characterised by loss of motor automatic function, muscle stiffness (rigidity), slowness of movement (bradykinesia) in patients, and in advanced stages leads to dementia and severe axial disorders. Most cases of PD are sporadic (90%) with several risk factors [45, 67] . PD is associated with a loss of dopaminergic neurons in the SN pars compacta (pc) and the appearance of aggregated α-synuclein inclusions, called Lewy bodies, in neurons [70, 146] . Overexpression of α-synuclein leads to PD and mutations in α-synuclein are linked to familial PD [46, 167] . Iron accumulation in neurons and glia of the SN is an established feature of PD with iron concentrations correlated with severity of disease [52, 53, 98, 169] . Further, iron can promote conformational change of α-synuclein from α-helical to the β-sheet structure that is observed in Lewy bodies [64] . However, iron alone does not seem to be sufficient to induce neuronal death. This is supported by the observation that mouse SNpc, which contains 25% less iron than adjoining SN pars reticulata, is selectively vulnerable to neurodegeneration [95] . This selective degeneration of SNpc despite relatively lower iron accumulation compared to unaffected adjoining tissue could be attributed to the colocalisation of dopamine and iron in the SNpc or on additional factors such as the presence of neuromelanin in the region that may exacerbate ironmediated oxidative damage [66, 95, 236, 242] . The variability in tissue ferritin levels in these regions may contribute to these differences in vulnerability to iron accumulation. The vulnerability of SNpc could be also explained by the high-energy demands due to the neurons autonomous pace-making activity. A higher energy demand renders the SNpc more susceptible to imbalances in labile iron levels and ensuing reactive oxygen species production [89] .
In addition to elevated iron in the SN of PD patients there is further evidence of dysregulation of iron homeostasis. Levels of several key iron homeostasis proteins are aberrantly altered in PD. In post-mortem PD brains a sustained activity of IRP1 has been reported in the SN which may be sufficient to limit ferritin levels, and increase neuronal iron uptake by increasing TfR1, and sensitise melanised neurons of the SNpc to iron-associated oxidative damage [68] . Indeed, ferritin levels are reported to be significantly lower in the SN of PD patients compared to those in healthy controls [38, 50] . Elevated levels of DMT1 along with diminished ferroxidase activity of Cp have been observed in PD patients and animal models of PD the effect of which may lead to the reported increase in iron levels [9, 21, 157, 182] . Interestingly, in tau knockout mice, where the loss of function of tau leads to impaired APPmediated iron export, a concomitant increase in iron is seen in the SN accompanied by marked neuronal loss, cognitive deficit and parkinsonism; these can be prevented through iron chelation [120] [121] [122] [123] . Further, APP levels are decreased in SN dopaminergic neurons in human PD patients while APP knockout in mouse models results in iron-dependent neuronal cell death in the SN [10] . Taken together these data suggest iron dysregulation as a common feature in AD and PD pathology.
Clinical assessment of iron chelation
Regarding the promising effects obtained in neurodegenerative animal models with iron chelators, clinical trials were conducted to examine the effect of iron removal therapy.
Iron chelation and metal targeted strategies in AD
To our knowledge, there is one reported phase 2 clinical trial of an iron chelator for the treatment of AD [42] . In this two-year single-blind study 48 patients were randomised to be treated intramuscularly with deferoxamine (DFO) 125 mg twice daily, 5 days per week, compared to oral placebo, or no treatment. They reported that the treatment halved the rate of clinical progression of dementia associated with AD compared with the controls.
A phase 2, randomised, placebo-controlled clinical trial using deferiprone is currently in progress (NCT03234686). The primary objective of this trial is to investigate the safety and efficacy of deferiprone, 15 mg/kg (twice a day, orally) in participants with prodromal AD and mild AD, who are confirmed by PET scan to have brain amyloid.
Iron chelation in PD
The first pilot iron chelation therapy in PD was a one year doubleblind, randomised, placebo-controlled clinical trial, in early-stage PD patients on stabilised dopamine regimens treated with deferiprone (30 mg/kg/day). A slower disease progression was observed in the early start group (patients who started the iron chelator 6 month earlier). Indeed, at 12 months the early start group retained a significantly lower motor handicap [1 point on the motor Unified Parkinson's Diseases Rating Scale (UPDRS): 21.3 ± 8] compared to the delayed start group (22.8 ± 6), indicating a disease modifying effect. Concomitantly, iron content of the SN and markers of oxidative stress was significantly decreased compared to baseline [48] . Positive clinical outcomes were recently confirmed by another randomised double-blind, placebo-controlled trial in early-onset PD patients. In this smaller sized trial, deferiprone reduced dentate and caudate nucleus iron content and indicated a trend for improvement in motor-UPDRS scores and quality of life [136] . In both trials deferiprone had a good safety profile; despite the requirement of weekly blood counts during the first 6 months to monitor reversible neutropenia that may occur in 1-3% (agranulocytosis in 0.8%) of patients treated with deferiprone. It has also been demonstrated that patients with lower Cp activity in the CSF and serum may respond better to iron chelation [86] .
A large phase 2, randomised clinical trial with PD patients receiving either deferiprone (30 mg/kg/day) or placebo is currently in progress (NCT02655315). The aim is to evaluate the effects of iron chelation on motor and non-motor handicap. Another phase 2 clinical trial (NCT02728843) is in progress to evaluate the effects of deferiprone at four different dosages in patients with PD and to assess the motor score with the Movement Disorder Society (MDS)-UPDRSIII.
Iron chelation in ALS
The first evidence of the iron chelation potential for ALS was recently described in a single-center, one-year pilot clinical trial [152] . Twenty-three patients were enrolled and received deferiprone treatment (30 mg/kg/day) for a year. The results showed a good safety, a significant decrease in the ALS Functional Rating Scale and the BMI after 3 months of treatment compared to previous 3 months of treatment-free period. Moreover, iron levels measured by magnetic resonance imaging, cerebrospinal fluid levels of oxidative stress and neurofilament light chains were lower after deferiprone treatment. The efficacy of this new therapeutic modality is now under investigation in a randomised, double-blind, placebo-controlled, multicenter study (NCT03293069).
Iron chelation in other neurological conditions
In Friedreich's ataxia, tolerance and efficacy of iron chelator was first demonstrated in a monocentric open label small phase 2 trial in nine adolescent patients treated 6 months with deferiprone (20-30 mg/ kg/day). Iron content of the dentate nuclei was significantly decreased in patients and a moderate neurological improvement observed in the youngest ones [19] . Few years later, similar results were obtained in an open-label clinical trial combining idebenone and deferiprone [215] . Then, a 6-month randomised, double-blind, placebo-controlled study was conducted with 72 patients treated with 3 different dosages of deferiprone (20, 40 or 60 mg/kg/day) or placebo [158] . Investigators concluded that the lower dose of deferiprone was well tolerated by Friedreich's ataxia patients and, for those with less severe disease, a possible benefit on ataxia and neurological function observed with this lower dose.
In 2015, safety, tolerability and efficacy of PBT2 was conducted in a phase 2, randomised, double-blind, placebo-controlled trial in HD patients. This iron chelator was administered for 26 weeks to adults with early stage to mid-stage HD daily at two different doses (250 and 100 mg). This clinical trial demonstrated a good safety and tolerance of this drug in HD patients (NCT01590888, Huntington study group).
Among the NBIA disorders, a 6-month phase 2 pilot trial was conducted in 9 patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone (25 mg/kg/day). No clinical changes were observed whereas a significant reduction of iron content in the globus pallidus was observed by magnetic resonance imaging [241] . In contrast, a 4-year follow up clinical trial on 6 PKAN patients treated with deferiprone at 15 mg/kg (twice a day, orally) confirmed the iron content reduction but also reported an improvement or stabilisation of motor symptoms [40] . This clinical improvement was also observed after 12 months of treatment in a recent pilot trial with 5 PKAN patients enrolled and treated with deferiprone at 30 mg/kg/day [180] . A large phase II trial is in progress.
Towards the new concept of conservative iron chelation: iron scavenging and redeployment
For any chelator to be of clinical value in disorders of regional siderosis they ought to be endowed with a requisite accessibility to the relevant sites and differential specificity so as to spare unaffected areas of the organism from scavenging an essential element [25] . Different agents with iron chelating features [e.g. DFO, clioquinol, VK28, M30 and natural plant-derived polyphenol flavonoids] have been assessed but not progressed to clinical trial testing for PD [153] .
Deferiprone is exceptional among iron chelators in its ability to cross membranes, including the BBB, and to chelate components of the cellular labile iron pool in brain tissue. Deferiprone has the remarkable ability to rescue transfusional hemosiderosis in the heart of β-thalassemia patients without inducing anaemia. This ability of deferiprone is largely attributable to the redeployment of captured iron to extracellular iron free Tf, and subsequent distribution (e.g. for uptake to ironsulfur cluster and haem biosynthetic machineries) [25] . Thus, this conservative repositioning strategy to subserve iron scavenging and redeployment is under assessment using deferiprone at the relatively low oral dose of 30 mg/kg/day in AD (NCT03234686), PD (NCT02728843 and NCT02655315) and ALS (NCT03293069).
Ferroptosis: a regulated cell death that harnesses the potential of iron
Overview
Ferroptosis is a newly described mode of regulated cell death that is triggered by a build-up of lipid peroxides and is prevented by iron chelation [55, 76, 175, 230, 234] . Lethal build-up of lipid ROS in the absence of mechanisms to mitigate their damage leads to ferroptotic cell death that is biochemically and morphologically distinct from other cell death modalities such as apoptosis (Fig. 4) [76] . While an inceptive pathway describing known key players of ferroptosis is now available, the exact role played by iron in the execution of ferroptosis is yet to be ascertained (Fig. 2) .
Glutathione peroxidase 4 (GPX4), a selenoprotein enzyme, is regarded as a critical enzyme that regulates ferroptosis. GPX4 catalyses the reduction of lipid peroxides in a reaction dependent on the availability of its cofactor, reduced glutathione (GSH). Molecules that can impede GPX4 activity directly (e.g. RSL3) or indirectly, through depleting levels of GSH (e.g. erastin), are potent inducers of ferroptosis (Table 1) [55, 80, 193, 234] . Inhibition of GPX4 results in a build-up of fatty acid radicals ultimately leading to ferroptotic death [232] . Correspondingly, molecules that mitigate lipid peroxides (e.g. vitamin E, liproxstatin-1, zileuton, and ferrostatin-1) serve as protective agents against ferroptosis [228] . Acyl-CoA synthetase long-chain family member 4 (ACSL4) is implicated as a major driver of ferroptosis [58] . ACSL4 generates the acyl Co-A derivatives of arachidonic acid (AA) or adrenic acid (AdA) which are esterified with phosphoethanolamine (PE) by the action of lysophosphotidylcholine acyltransferase 3 (LPCAT3). These AA-PE and Ada-PE esters may then be oxidised to generate lipid hydroperoxides (LOOH) through the enzymatic action of lipoxygenases and/or through autoxidation reactions (Fig. 2) [58,192] . Fig. 4 . The ferroptosis pathway and its inhibitors are distinct from apoptosis. Cells undergoing ferroptosis are morphologically and biochemically distinguishable from apoptotic cells. Ferroptotic cells display reduced mitochondrial size and crista and ultimately display membrane rupture while features associated with apoptosis, such as chromosomal condensation and apoptotic bodies, are absent. Ferroptosis is propagated, whereas apoptosis is immune silent. Ferroptosis is inhibited completely by iron chelation while this has no effect of apoptosis. Conversely, inhibitors of apoptosis that affect caspase function do not perturb ferroptotic death.
Ferroptotic susceptibility is contingent upon cellular status of GSH, lipid antioxidants, polyunsaturated fatty acids (PUFA) and lipids, selenium availability, and aspects of molecular crosstalk such as activation of mitogenic pathways (Ras-Raf-MEK-ERK) and tumour suppressor p53 protein [58, 83, 108, 110, 125, 138, 139, 205, 220, 228] .
Ferroptosis is reliant on the availability of iron either imported or liberated through autophagic/lysosomal degradation of ferritin (ferritinophagy) or through catabolism of haem [55, 78, 115, 138, 175, 234] . Cells can be made refractory to ferroptosis through genetic ablation of iron uptake (TfR1), metabolism (IRP2 and ISCU), and storage (ferritin H) genes [27, 55, 234] , or through depleting Tf in the extracellular milieu [79] . Further, ferroptosis can be prevented by iron chelators (e.g. DFO, 2,2-bipyridyl or compound 311) [55, 175, 234] . Ferroptosis initiated through repression of the p53-upregulated target, SLC7A11, which encodes a component of the cysteine/glutamate antiporter (xCT), results in iron-dependent accumulation of ROS and GSH depletion [27, 55, 110] . Erastin induces ferroptosis through inhibiting the activity of SLC7A11 [56] , and was recently demonstrated to enhance iron bioavailability through autophagic/lysosomal degradation of ferritin and its cargo receptor NCOA4 [78] . Thus ferroptosis appears to depend on the bioavailable iron pool with evidence of changes in iron flux prior to the execution of ferroptosis [4] (Fig. 2) .
The exact function of iron in ferroptosis remains elusive. One possibility is that iron catalyses the formation of lipid peroxides directly through its oxidative potential involving Fenton chemistry [192] . Alternatively/additionally, iron may facilitate generation of lipid peroxides through iron-dependent oxidases. Lipoxygenases are non-haem iron-containing enzymes that can catalyse dioxygenation of PUFAs in lipids generating the proximate inducers of ferroptosis [58] . Another possibility is that iron may play multiple roles in the ferroptosis pathway both upstream and downstream of effector molecules and some of these functions may be independent of its redox activity [58, 77] .
Implications of ferroptosis in disease and physiology
The initial discovery of ferroptotic cell death in a subset of cells that harbour oncogenic Hras highlighted the relevance of ferroptosis in certain cancer types [55, 59, 234] . Ferroptosis is implicated in the oncosuppressive function of p53, in the context of failing antioxidant defences, by negatively regulating SLC7A11, a ferroptosis regulator that is highly expressed in human cancers and is implicated in resistance to chemotherapeutics [33, 75, 103, 110, 179, 235] . ACSL4, a central ferroptosis executor, is found elevated in malignancies such as liver [203] , prostate [144, 227] and breast cancers [144] which may therefore be susceptible to ferroptotic chemotherapeutics [58, 132] . Additionally, renal cell carcinomas and large B cell lymphomas may be particularly sensitive to ferroptosis in a GPX4-dependent manner [233] . Therapyresistant cancer cells show a unique sensitivity to ferroptosis and may be a target for ferroptosis based therapies [58, 217] .
Aberrant ferroptosis activation may lead to pathological consequences. Ischemia-reperfusion injury (IRI) of the liver and kidneys has been shown to involve ferroptosis; these can be rescued by ferroptosis inhibitors in vivo [72, 126, 137] . Ferroptosis may also contribute to myocardial infarction and IRI [11, 133] . We have recently shown that ferroptosis has a bearing on ischemic stroke which can be mitigated by ferroptosis inhibitors [210] . In addition, dysregulated ferroptosis may lead to degenerative disorders of photoreceptor cells [211] , abnormal skin phenotypes [189] , and a host of disorders related to improper development of vasculature [226] . Aberrant ferroptosis activation in T cells of the immune system has been shown to affect their ability to mount a response to Leishmania parasite infection [140] .
While the significance of ferroptosis in various pathological settings has been determined, a specific physiological role, in addition to a general anti-proliferative function, is yet to be ascribed. However, recently ferroptosis has been indicated as a possible arm of the innate immune response that is specialised against intracellular pathogens, such as the malarial pathogen Plasmodium [112] .
Role of ferroptosis in AD
AD results from loss of synapses and neuronal cell death in the brain. The chronic inflammation and degeneration that accompanies AD and the absence of downstream indicators of apoptotic death suggest that an alternate cell death mechanisms may be involved [91, 113, 173] . Elevated brain iron is associated with increased risk of AD and affected regions in the brain show elevated iron. Interestingly, levels of CSF ferritin can strongly indicate the progression of mild cognitive impairment to AD, with higher CSF ferritin predictive of earlier conversion to AD [6] . Further, quantitative susceptibility mapping (QSM) value, a measure of magnetic susceptibility of tissue determined by MRI and used as a proxy for iron level in tissue, of the hippocampus indicated that abnormal levels of elevated iron may not be required for AD progression. However, individuals with Aβ pathology that show higher iron, but within normal range, deteriorate faster than those with lower iron [7] . Furthermore, α-lipoic acid, which can stabilize cognitive function of AD patients by limiting tau hyperphosphorylation, was recently shown to mitigate tau-induced iron overload and accompanied lipid peroxidation in P301S Tau transgenic mice [238] . These observations implicate a possible involvement of ferroptotic processes as iron appears to accelerate disease progression.
Lipid peroxidation, a hallmark feature of ferroptosis, is considered an early event in the pathology of AD [168, 176] . Proteins involved in antioxidant, neuronal communication, neurite outgrowth and energy metabolism are modified thorough extensive binding to 4-hydroxy-2-nonenal (HNE) which is a proximal marker for lipid peroxidation [176] . a) Decreases GPX4 levels a) Coenzyme Q10 depletion [193] FINO2 a) GPX4 inactivation a) Iron oxidation [80] t-butyl hydroperoxide (TBH) Enhanced ROS/lipid peroxidation [110, 222] Deuterated PUFAs (D-PUFA), which may delay ferroptosis, mitigate lipid peroxidation in brain tissue and also reduce Aβ in a mouse model of AD (APP/PS1 transgenic mice) [172, 232] . Recently, the conditional ablation of GPX4 in the forebrain (cerebral cortex and hippocampus) of mice (Gpx4BIKO) was shown to result in AD-like cognitive impairment (special learning and memory) accompanied by hippocampal neurodegeneration, elevated lipid peroxidation (enhanced HNE adducts observed in the cerebral cortex) and neuro-inflammation [91] . These phenotypes were further exacerbated in mice fed with a diet deficient in tocopherol, a lipid soluble antioxidant that serves as a natural antiferroptotic compound in the body [91] . Further, AD is accompanied by depletion of GSH in the frontal cortex and hippocampus which correlates with decline in cognitive function [134] . Taken together these data suggest an important role of ferroptosis in AD.
Role of ferroptosis in PD
Pathological progression of PD displays features that may facilitate ferroptosis induction such as elevated iron in the SNpc [49, 57, 88, 122] , depleted GSH [194] and lipid peroxidation [51] . Iron chelation has been shown to mitigate the motor impairment in mouse models of PD [8, 120, 122] , and in a human clinical trial [48] . Further iron chelation was found to enhance GPX activity in the CSF [48] . Similarly, N-acetylcysteine (NAC), an antioxidant that can enhance brain GSH, offers partial protection against neurodegeneration in PD mouse models [36, 159, 164] . Further, a recent short term (3 months) phase II clinical trial (NCT02445651) indicated protection of dopaminergic neurons in the caudate and putamen in PD patients receiving NAC with concomitant significant improvement in clinical symptoms [145] .
A recent study characterised erastin-induced ferroptosis in a cell culture model of PD [Lund human mesencephalic cells (LUHMES)] and ex vivo using organotypic slice cultures. Further, the study showed that the ferroptosis inhibitor, ferrostatin-1, can prevent neuron loss and behavioural impairment in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse PD model [57] . Further, cell death initiated in LUHMES cells using environmental neurotoxins such as rotenone and paraquat, that are causally associated to sporadic PD, was rescued by the iron chelator deferiprone, ferrostatin-1 and liproxstatin-1 [57] . Taken together, these studies indicate that ferroptosis inhibitors may be effective in PD.
Ferroptosis in other neurological conditions
Cell death mechanisms associated with neurological impairment remain poorly understood. However, conditions that may favour ferroptosis, such as elevated brain iron and diminished GSH, conspicuously appear across multiple neurodegenerative and certain psychiatric disorders [15, 44, 71, 81, 134, 190] .
ALS/MND
ALS/MND is a progressive neurodegenerative disorder characterised by a selective dysfunction of the cortical and spinal motor neurons [74] . While genetic mutations cause up to 10% of cases of ALS [Familial ALS (FALS)], adult-onset motor neuron disease leading to sporadic ALS (SALS) has an unknown aetiology [216] . Several conditions that may predispose cells to ferroptotic death have emerged as possible biomarkers of ALS hinting at a causal role of ferroptosis [32, 35, 74, 152, 196] . These include aberrant iron accumulation in mouse models of ALS, as well as in SALS and FALS [74, 152, 216] . Iron chelation using deferiprone has been recently shown to enhance mean lifespan in a mouse model of ALS (SOD1 G86R ) and has shown benefits (e.g. stabilised BMI) in a small cohort (n = 23) of ALS patients [152] . Furthermore, ALS patients express enhanced lipid peroxidation in the CSF and sera, as well as decreased GSH levels in motor cortex, consistent with ferroptosis [35, 196] . In a mouse model of ferroptosis (Gpx4NIKO) the ablation of Gpx4 in neurons led to a rapid paralysis, severe muscle atrophy and death which was associated with the ferroptotic degeneration of motor neurons of the spinal cord, recapitulating cardinal features of ALS [32] . Furthermore, no overt neurodegeneration in the cerebral cortex was observed in the Gpx4NIKO mice or in another mouse model [Gpx4(f/f);Camk2α-creERT] where Gpx4 was selectively ablated in cortical neurons, underscoring the vulnerability of spinal motor neurons to GPX4-dependent ferroptosis [32] .
Stroke
Stroke is a major cause for morbidity and disability resulting from interruption of blood supply to the brain. Ischemic stroke, accounting for a majority of stroke cases (~85%), results from vascular occlusion [118, 210] . Spontaneous intracerebral haemorrhage (ICH), which leads to 15% of all strokes, is a cause of great morbidity and mortality with few therapeutic avenues [60] . Ischemic and haemorrhagic stroke may lead to ferroptotic death of neurons [124, 210, 239, 240] . Acute focal cerebral ischemia induced in mice through transient middle cerebral artery occlusion (MCAO) leads to enhanced brain iron. Reperfusion damage following MCAO is exacerbated in aged mice and those fed on high-iron feed [29, 122, 210] . Recently ferroptosis inhibitors, ferrostatin-1 and liproxstatin-1, were shown to mitigate neuronal damage when administered intranasally immediately following MCAO/reperfusion [210] . These agents were also effective to a lesser extent when administered 6 h following MCAO/reperfusion. Other ferroptosis mitigating interventions, such as limiting brain iron through administration of Cp or APP ectodomain, or the use of 15-lipoxygenase-1 inhibitor, ML351, inhibited ischemia-reperfusion mediated brain damage [210] . Similarly, ferrostatin-1 administration in the affected region of an induced ICH mouse model reduced neurodegeneration and neurological deficit and also rescues haem/haemoglobin induced cell death in cultured primary neurons and organotypic hippocampal slice cultures [124, 240] . Taken together ferroptosis signalling may be involved in neuronal cell death following stroke and targeting this cell death pathway may be a therapeutic option to mitigate stroke associated pathology.
Friedreich's ataxia
Friedrich's ataxia is an autosomal recessive inheritable neurological condition that leads to progressive ataxia of limbs and sensory loss. The disease is linked to mutations in the FXN gene which results in reduced synthesis of the protein, frataxin. Frataxin is important for iron-sulfur cluster assembly in the mitochondria and the reduction in the levels of this protein thus leads to mitochondrial dysfunction and iron accumulation. Isotope-reinforced D-PUFAs that attenuate lipid peroxidation (and hence anti-ferroptotic) were found to be protective in a cell culture models of Friedreich's ataxia (murine fibroblasts and primary human Friedreich's ataxia fibroblasts) [41, 232] . Further, agents that may enhance ferroptotic susceptibility, PUFAs (by enhancing lipid peroxidation), BSO (by depleting GSH), and iron (provided as ferric ammonium citrate) exacerbated toxicity in these cell culture models [41] . The combination treatment of D-PUFAs and another known anti-ferroptotic compound, idebenone, showed enhanced efficacy to protect against GSH depletion and iron in these model systems [41, 193] .
In another study, deferiprone and NAC when applied as a combined therapy were able to attenuate mitochondrial dysfunction induced because of iron accumulation in the brains of rats on high iron diet [200] . In a recent study a small cohort of patients (n = 5) treated with deferiprone (20 mg/kg/day) in combination with idebenone followed for 10-24 months showed improved neurological function [65] . Taken together, these studies highlight a possible contribution of ferroptosis in Friedreich's ataxia.
Conclusion and future perspectives
AD and PD continue to be major health challenges with the situation set to worsen as global populations continue to age. With little to no progress in treatment modalities new hypothesis are required to treat, if not explain, neurodegenerative process associated with these debilitating conditions. Iron dysregulation in the brain implicated in these and several other neurodegenerative disorders coupled with deeper understanding of iron-mediated/dependent cell death pathways, such as ferroptosis, may offer interesting and new therapeutic avenues. While anti-ferroptotic molecules show remarkable potency in vitro their clinical use is limited due to their inability to cross the BBB. Thus, there is a potential to develop the next class of molecules that may breach this barrier. Possible strategies may include conjugating anti-ferroptotic molecules to BBB-permeable peptides or packaging anti-ferroptotic agents within nanoparticles or liposomes that allow for specific uptake across the BBB [17, 73, 107, 128] . Iron chelators that can cross the BBB are under investigation in clinical settings now. Anti-ferroptotic therapies based on iron chelation may be advantageous as they may mitigate a broad range of neurodegenerative processes. In the future a better understanding of the effector arm of ferroptosis may offer a range of theranostic opportunities.
